Alzamend Neuro, Inc. · NASDAQ:ALZN
Alzamend Neuro — Investor Presentation (April 2023)
28 slides from Alzamend Neuro's investor presentation, Apr 25, 2023
Slide 1: Corporate Presentation April 2023
Alzamend Neuro, Inc. Corporate Presentation April 2023
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the “Company” or “Alzamend”) contain “forward looking statements” within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Sect
Slide 3: Table of Contents
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. TABLE OF CONTENTS 3 4 - 8 Company Overview Introduction 9 Alzheimer’s Disease Overview of Alzheimer’s Disease 10 Economic Burden 11 Therapeutic Landscape 12 General Scientific Overview Our Science 13
Slide 4: Company Overview: Introduction
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION NASDAQ: ALZN 4 Biopharmaceutical Industry Small Molecule / Cell Therapy Sector 2016 Founded June 15, 2021 IPO $7.4 Million (Per our 10 - Q filed on March 15, 2023) Last R
Slide 5: Lead Drug Candidate – Ionic Cocrystal of Lithium (AL001)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Lead Drug Candidate – Ionic Cocrystal of Lithium (AL001) 5 Market Opportunity Bioequivalent to Marketed Lithium Therapies Multiple Indications » 43.5 million U.S. patient
Slide 6: Reference to AL001: Current Marketed Lithium – Lithium Carbonate
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Reference to AL001: Current Marketed Lithium – Lithium Carbonate 6 Published Clinical Efficacy Studies For Alzheimer’s Challenges Usage For BD , MDD, PTSD » Forlenza , 20
Slide 7: Pipeline
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. 7 FDA Approval Phase III Phase II Phase I Pre - Clinical Indication Product Candidate • Alzheimer’s Disease AL001 • Bipolar Disorder • Major Depressive Disorder • Post - Traumatic Stress Disorder • Al
Slide 8: Company History and Current Pipeline
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Company History Current Pipeline 8 AL001 (aka LISPRO): • an ionic cocrystal of lithium for the potential treatment of Alzheimer’s Disease, BD, MDD and PTSD. ALZN002 (aka
Slide 9: Overview of Alzheimer's Disease
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzheimer’s Disease OVERVIEW OF ALZHEIMER’S DISEASE 9 Alzheimer’s Disease: Alzheimer’s Disease is an irreversible, progressive brain disorder that slowly destroys memory and cognitive skills , and eve
Slide 10: Economic Burden
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Important Implications Economic Burden 1. In 2023, the estimated healthcare costs for treating individuals with Alzheimer’s Disease in the United States will be $345 billion , including $222 billion i
Slide 11: Therapeutic Landscape
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Therapeutic Landscape 11 OVERVIEW OF ALZHEIMER’S DISEASE https://alz - journals.onlinelibrary.wiley.com/pb - assets/hub - assets/alz - journals/infographic/TRCI - Drug - Pipeline - Infographic - 2022
Slide 12: Overview of Our Science
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Our Science GENERAL SCIENTIFIC OVERVIEW 12 Status Strength Synopsis Therapeutic Drug ▪ Initiated a Phase IIA Multiple Ascending Dose Clinical Trial in May 2022 (www.clinicaltrials.gov, ide
Slide 13: AL001 Phase I Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 Phase I Trial 13 Status Description Study Title Study No. Completed • To assess the relative bioavailability of the AL001 lithium formulation relative to a marketed lithium carbonate formulation
Slide 14: Select Results from Phase I Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Safety/Tolerability: Primary Endpoint Met Select Results from Phase I Trial 14 » AL001 was shown to be safe and well - tolerated in healthy adult subjects » No serious adverse events and no deaths wer
Slide 15: AL001 Phase IIA Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 Phase IIA Trial 15 Status Description Study Title Study No. • Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial completed in March 2023 (www.clinicaltrials.gov, identifier: NC
Slide 16: ALZN002 Phase I/IIA Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. ALZN002 Phase I/IIA Trial 16 Status Description Study Title Study No. Phase I/IIA Clinical Trial Initiated in March 2023 ( www.clinicaltrials.gov, identifier: PENDING ). • Primary: • To assess the saf
Slide 17: AL001 (aka LISPRO)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO ) 17 • AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium , proline and salicylate • AL001 exhibits improved non - clinical pharmacokineti
Slide 18: AL001 (aka LISPRO) Preclinical Results
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO) 18 The results of our preclinical studies, conducted from May 2016 to June 2017 , are summarized below : • AL 001 had no effect on renal COX 2 activity ( Tg - Ctrl vs . AL 001 : p >
Slide 19: AL001 (aka LISPRO) Preclinical Studies
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO) 19 • Our pre - clinical studies encompassed the treatment of 28 transgenic (or genetically modified) and 10 non - transgenic mice with lithium carbonate and AL001. • Female APPSWE/P
Slide 20: Overview of ALZN002 (aka E22W)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of ALZN002 (aka E22W) 20 • Our goal is to develop an Alzheimer’s Abeta vaccine candidate that will be devoid of the problems associated with current vaccine therapies. Our studies concluded t
Slide 21: Overview of ALZN002 (aka E22W)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of ALZN002 (aka E22W) 21 • We illustrated our result by using Abeta peptide pulsed Dendritic Cells (“DC”) as a vaccine in Tg APP/PS1 mice. • ABeta 1 - 42 with different mutation were synthesi
Slide 22: Overview of Alzamend Neuro's Intellectual Property (Licensed Patents)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Alzamend Neuro’s Intellectual Property (Licensed Patents) ALZAMEND NEURO 22 Patent # Expiration Date Date Issued Date Filed Therapeutic Drug Patent Type Title of Patent 9,603,869 05/21/203
Slide 23: Overview of Top Alzheimer's Disease Drugs on the Market
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Top Alzheimer’s Disease Drugs on the Market 1 COMPETITIVE LANDSCAPE Aricept Exelon Namenda Razadyne A Aricept – Eisai Co., Ltd., Financial Results for Fiscal 2020(3/31/2021 for JPY FX) ( h
Slide 24: Overview of Market Opportunity for AL001 and ALZN002
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Market Opportunity for AL001 and ALZN002 COMPETITIVE LANDSCAPE 24 Global (Including US) United States Patient Population 280 Million² 21 Million¹ MDD 284 Million² 9 Million¹ PTSD 55 Millio
Slide 25: Alzamend Leadership Team
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzamend Leadership Team ALZAMEND NEURO 25 Stephan Jackman Chief Executive Officer and Director 20+ years multi - industry experience, specialized in Biotech and Pharmaceutical Kenneth S. Cragun Senio
Slide 26: Alzamend Scientific Advisory Board
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzamend Scientific Advisory Board ALZAMEND NEURO 26 Thomas M. Wisniewski, M.D. Director, NYU Langone’s Pearl I. Barlow Center for Memory Evaluation and Treatment 300+ Peer - Reviewed Medical Journal
Slide 27: Alzamend Board of Directors
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Lynne Fahey McGrath, Ph.D. Regulatory Affairs and Product Development Consultant 30+ years experience, Biotech and Pharmaceuticals M.P.H./Ph.D., Public Health from UMDNJ – Robert Wood Johnson Medical
Slide 28: Contact Us
CONTACT US 3480 Peachtree Road NE 2 nd Floor, Suite 103 Atlanta, GA 30326 +1 (844) 722 - 6333 Info@alzamend.com www.alzamend.com